Safetyslug – MannKind Stock Skyrockets 39% After New Ralinepag DPI Development Deal With United Therapeutics. MannKind (NASDAQ: MNKD) shares surged 39.28% in morning trading after the company unveiled a new dry powder inhalation (DPI) development program for ralinepag in partnership with United Therapeutics Corporation.
The company announced it has developed a dry powder inhaled formulation of ralinepag, known as MNKD-1501, for United Therapeutics under an expanded licensing and collaboration agreement. Under the terms of the deal, MannKind is eligible to receive up to $35 million in development milestone payments, along with 10% royalties on net sales.
Phase 3 Success of Ralinepag Strengthens Commercial Potential
The announcement comes after United Therapeutics reported in March that its pivotal long-term Phase 3 ADVANCE OUTCOMES study of extended-release ralinepag tablets for pulmonary arterial hypertension successfully met its primary endpoint with strong statistical significance.
That clinical success adds major commercial credibility to the new DPI program, as investors now see MNKD-1501 as a potentially valuable inhaled expansion of a clinically validated therapy.
Tyvaso DPI Success Sets a Powerful Benchmark
Investor enthusiasm is also being fueled by MannKind’s prior success with United Therapeutics.
The original 2018 agreement between the two companies led to the successful development and FDA approval of Tyvaso DPI in May 2022. In 2025, United Therapeutics reported that Tyvaso DPI generated $1.3 billion in revenue, establishing a clear benchmark for what MNKD-1501 could potentially achieve if commercialization follows a similar path.
This new announcement also marks a major sentiment reversal from February 2026, when United Therapeutics introduced TreSMI, a soft mist inhaler that directly challenged MannKind’s Tyvaso DPI franchise and contributed to nearly a 40% drop in MannKind shares at the time.
Broader Market Rally and Upcoming Earnings Add Momentum
Today’s move is also supported by a strong broader market backdrop, with:
- S&P 500 up 1.10%
- Dow Jones rising 1.28%
- NASDAQ gaining 1.28%
MannKind is also scheduled to report Q1 2026 earnings on May 6 after market close, adding another major near-term catalyst that is drawing investor attention.
Analyst Outlook Remains Mixed but Suggests Undervaluation
Wall Street coverage has been somewhat mixed:
- H.C. Wainwright lowered its target price from $11 to $8 while maintaining a Buy rating
- Leerink Partners maintained its Outperform rating, signaling continued confidence that the stock may be undervalued
Despite prior caution, today’s partnership expansion substantially reshapes the narrative around MannKind’s future growth.
Why MNKD Is Rallying So Sharply Today
The new ralinepag DPI deal reframes MannKind’s relationship with United Therapeutics as an evolving growth partnership rather than a competitive threat.
Key bullish drivers include:
- Immediate $5 million payment
- Up to $35 million in milestone opportunities
- 10% royalty rights on net sales
- A Phase 3-backed drug candidate
- Proven precedent from Tyvaso DPI’s billion-dollar revenue trajectory
- Upcoming Q1 earnings catalyst
Together, these factors created a powerful catalyst mix that is driving MannKind sharply higher today.
Watching MNKD for a Trading Setup?
Many traders can identify chart patterns, but execution timing is often the real challenge.
Advanced visual AI trading tools are increasingly helping traders bridge that confidence gap by analyzing chart structures in real time and generating actionable strategies — including entry points, stop-losses, and profit targets in under a minute, offering clearer next steps when momentum opportunities like MNKD emerge.